Group 1 - Aikolan's controlling shareholder Liu Yi terminated the share transfer agreement for 4 million shares, which represents 5% of the company's total share capital, with no change in control [1] - Wancheng Group announced a cash dividend of 4.00 yuan per 10 shares, totaling 71.9959 million yuan, with the record date on May 19, 2025 [1] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation, acquiring a total of 7% equity in the company [2] Group 2 - China Resources Double Crane's subsidiaries received approval for two drugs, indicating progress in their product pipeline [3] - Fosun Pharma's subsidiary's drug was included in the breakthrough therapy program, highlighting its innovative potential [4] - Zhongheng Group's subsidiary received approval for naloxone injection, enhancing its product offerings [5] Group 3 - Shenzhen Airport reported a passenger throughput of 5.3202 million in April, a year-on-year increase of 23.50% [8] - Hangzhou Bank successfully issued 5 billion yuan in technology innovation bonds, aimed at supporting tech innovation [10] - Jiuzhou Pharmaceutical received approval for a raw material drug used in treating severe depression, expanding its product range [12] Group 4 - Aihua Group reported a 25.38% decline in revenue for the first four months of the year, indicating potential challenges [27] - Changhua Group received a project designation notice from a well-known new energy vehicle company, with an expected total sales amount of approximately 108 million yuan [28] - Nanchao Food reported a slight revenue decrease of 0.98% in April, reflecting market conditions [30]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於維立西呱原料藥上市申請獲得批准的公告》僅供參 閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 5 月 13 日 证券代码：601607 证券简称：上海医药 公告编号：临2025-054 上海医药集团股份有限公司 关于维立西呱原料药上市申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-054 上海医药集团股份有限公司 关于维立西呱原料药上市申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属控股子公司南通常佑药业科技有限公司（以下简称"南通常佑"）的维立西呱 原料药（以下简称"该药物"）收到国家药品监督管理局（以下简称"国家药监 局"）颁发的《化学原料药上市申请批准通知书》（通知书编号：2025YS00363）， 该药物获得批准生产。 一、该药物基本情况 名称：维立西呱 注册标准编号：YBY64282025 包装规格：5kg/桶 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 截至本公告日，中国境内暂无维立西呱原料药的其他生产厂家。IQVIA 数据 库显示，2024 年全年中国大陆医院采购维立西呱制剂的金额约为人民币 8,421 万元。 三、对上市公司影响及风 ...

上海医药（601607）公告，控股子公司南通常佑的维立西呱原料药获国家药监局颁发的《化学原料药上 市申请批准通知书》，该药物主要适用于近期心力衰竭失代偿的症状性慢性心力衰竭成人患者，旨在降 低住院或急诊静脉利尿剂治疗的风险。维立西呱最早于2021年在美国上市，2023年南通常佑递交技术审 评申请并获受理，近日收到批准通知书。截至公告日，公司已投入研发费用约363万元。2024年全年中 国大陆医院采购维立西呱制剂的金额约为8421万元。该事项不会对公司当期经营业绩产生重大影响。 ...

Core Viewpoint - The article emphasizes the importance of enhancing the quality of listed companies in Shanghai, focusing on cultivating high-performing, innovative, and well-governed firms that are recognized in the market [1][2]. Group 1: Shanghai State-owned Enterprises Performance - As of the end of 2024, the total market value of 94 state-owned listed companies in Shanghai reached 2.78 trillion yuan, an increase of 617.74 billion yuan, or 28.52% from the beginning of the year [1]. - The Shanghai Municipal State-owned Assets Supervision and Administration Commission aims to complete high-quality reforms and enhance the market value performance of state-owned listed companies [2]. Group 2: Company Highlights Shanghai Port Group - In 2024, Shanghai Port Group achieved a container throughput of 51.506 million TEUs, a year-on-year increase of 4.8%, maintaining its position as the world's largest port for 15 consecutive years [3]. - The company's net profit attributable to shareholders reached 14.95 billion yuan, a growth of 13.3% year-on-year [3]. Huayi Group - Huayi Group reported a revenue of 44.6 billion yuan in 2024, a 9.3% increase year-on-year, with a net profit of 0.91 billion yuan, up 5.8% [5]. - The company applied for 151 patents, receiving 134 authorizations, and is focusing on strategic emerging sectors [5][6]. Shanghai Pharmaceuticals - Shanghai Pharmaceuticals achieved a revenue of 275.251 billion yuan, a 5.75% increase, and a net profit of 4.553 billion yuan, up 20.82% [6][7]. - The company is optimizing its R&D system and has established a new innovation center to enhance its open innovation ecosystem [7]. Pudong Development Bank - Pudong Development Bank reported a net profit of 45.3 billion yuan in 2024, a 23.31% increase, marking the highest growth in nearly 12 years [9]. - The bank is focusing on technology finance and has developed a comprehensive cross-border financial service system [10][11]. China Pacific Insurance - China Pacific Insurance reported a revenue of 404.089 billion yuan, a 24.7% increase, and a net profit of 44.96 billion yuan, up 64.9% [11][12]. - The company is enhancing its green insurance offerings and has provided coverage exceeding 147 trillion yuan in green insurance [13]. Data Harbor - Data Harbor achieved a revenue of approximately 1.721 billion yuan, an 11.57% increase, and a net profit of approximately 132 million yuan, up 7.49% [14][15]. - The company is focusing on IDC services and has been recognized as a top service provider in the industry [14].

Group 1: Core Insights - The Shanghai Municipal State-owned Assets Supervision and Administration Commission and the Shanghai Stock Exchange held a performance briefing to enhance the quality of state-owned listed companies and strengthen investor relations [1][2] - The total market value of 94 state-owned listed companies in Shanghai reached 2.78 trillion yuan, an increase of 617.77 billion yuan or 28.52% from the beginning of the year [1] Group 2: Company Highlights - Shanghai Port Group achieved a container throughput of 51.51 million TEUs, a year-on-year increase of 4.8%, maintaining its position as the world's largest port for 15 consecutive years [3] - Shanghai Port Group's net profit attributable to shareholders reached 14.95 billion yuan, a 13.3% increase year-on-year [3] - Huayi Group reported a revenue of 44.6 billion yuan, a 9.3% increase, and a net profit of 910 million yuan, up 5.8% [5][6] - Shanghai Pharmaceutical achieved a revenue of 275.25 billion yuan, a 5.75% increase, and a net profit of 4.55 billion yuan, a 20.82% increase [8][9] - Pudong Development Bank's net profit reached 45.3 billion yuan, a 23.31% increase, marking the highest growth in nearly 12 years [10][11] - China Pacific Insurance Group reported a revenue of 404.09 billion yuan, a 24.7% increase, and a net profit of 44.96 billion yuan, a 64.9% increase [13][14] - DataPort achieved a revenue of approximately 1.72 billion yuan, an 11.57% increase, and a net profit of approximately 132 million yuan, a 7.49% increase [15][16] Group 3: Strategic Initiatives - Shanghai Port Group is focusing on digital, intelligent, and green transformation to enhance its core business and sustainable development capabilities [3][4] - Huayi Group is advancing major technological projects and has filed 151 patents, with 134 granted [6][7] - Shanghai Pharmaceutical is optimizing its R&D system and has established a new innovation center to accelerate the development of a collaborative ecosystem [8][9] - Pudong Development Bank is implementing a digital finance strategy and enhancing its service efficiency through various digital platforms [10][11] - China Pacific Insurance is expanding its green insurance offerings and enhancing its technology-driven services [13][14] - DataPort is deepening its IDC service capabilities and has been recognized as a top service provider in the industry [15][16]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於控股股東及其一致行動人權益變動觸及 1%刻度的 提示性公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 5 月 10 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601 ...

Core Viewpoint - The announcement details a change in equity ownership by Shanghai Pharmaceuticals Holding Co., Ltd.'s controlling shareholder, Shanghai Industrial (Group) Co., Ltd., and its concerted party, Shanghai Industrial International Investment Co., Ltd., which has resulted in an increase in their shareholding without triggering a mandatory tender offer or affecting the company's control structure [1][2][3]. Group 1: Equity Change Details - The equity change is a result of the implementation of a previously disclosed share acquisition plan by Shanghai Industrial (Group) Co., Ltd. and its concerted party, which does not trigger a mandatory tender offer [1][3]. - Prior to the equity change, Shanghai Industrial (Group) held 1,371,116,337 shares, representing 36.974% of the total share capital of 3,708,361,809 shares. After the change, their holdings increased to 1,372,116,337 shares, accounting for 37.001% of the total share capital [2][3]. - The share acquisition plan is still ongoing, and the acquiring parties will continue to increase their shareholdings in accordance with the plan during the implementation period [1][2]. Group 2: Compliance and Legal Framework - The equity change complies with relevant laws and regulations, including the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, and the Management Measures for the Acquisition of Listed Companies [2][3]. - The company will continue to monitor the progress of the share acquisition plan and fulfill its information disclosure obligations as required by the relevant regulatory authorities [3].

证券代码：601607 证券简称：上海医药 公告编号：临 2025-053 上海医药集团股份有限公司 关于控股股东及其一致行动人权益变动触及1%刻度的提示性公告 上海实业（集团）有限公司及其一致行动人上实国际投资有限公司保证向本公 司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 名称：上实国际投资有限公司 本次权益变动系上海医药集团股份有限公司（以下简称"上海医药"或"公 司"）控股股东上海实业（集团）有限公司（以下简称"上实集团"）及其一致行 动人上实国际投资有限公司（以下简称"上实国际"）履行此前披露的增持股份计 划所致，不触及要约收购，不会导致公司股份分布不具备上市条件，亦不会导致 公司控股股东及实际控制人发生变化。 本次权益变动前，上实集团合计持有上海医药 1,371,116,337 股，占公司 总股本的 36.974%。本次权益变动后，上实集团合计持有上海医药 1,372,116,337 股，占公司总股本的 37.001%。本次增持计划尚未实施完毕，增持主体将继续按照 相关增持计划，在增持计划实施 ...

Investment Rating - The report maintains an "Outperform" rating for Shanghai Pharmaceuticals [2][16]. Core Insights - In Q1 2025, Shanghai Pharmaceuticals achieved revenue of CNY 70.76 billion, a year-on-year increase of 0.9%, while net profit attributable to shareholders was CNY 1.33 billion, down 13.6% year-on-year, primarily due to a decline in profit contributions from the Pharmaceutical Manufacturing segment and one-time losses [3][13]. - The Pharmaceutical Service segment demonstrated strong resilience, with revenue reaching CNY 64.88 billion, up 2.6% year-on-year, driven by innovative business initiatives [3][14]. - The report forecasts revenue growth of 8% for FY2025 and 7.3% for FY2026, with net profit growth expected to be 9.3% in FY2025 and 9.9% in FY2026 [11][16]. Financial Performance Summary - Revenue for FY2023 was CNY 260.3 billion, with a projected increase to CNY 275.3 billion in FY2024 and CNY 297.3 billion in FY2025, reflecting a growth rate of 12.2%, 5.7%, and 8.0% respectively [11][16]. - The gross profit margin for FY2025 is projected at 11.2%, with a slight decrease to 11.1% in FY2026 [11][16]. - The report indicates a P/E ratio of 7.4x for FY2025 and 6.7x for FY2026, suggesting the stock is undervalued compared to its earnings potential [5][16]. Segment Performance - The Pharmaceutical Service segment's revenue includes CNY 1.8 billion from Contract Sales Organization (CSO) services, up 9.9% year-on-year, and CNY 12.5 billion from innovative drug distribution, up 23.2% year-on-year [3][14]. - The Pharmaceutical Manufacturing segment reported revenue of CNY 5.89 billion, down 15.3% year-on-year, primarily due to a high base effect from the previous year [14][16]. Valuation - The target price for Shanghai Pharmaceuticals is set at HKD 13.73, based on a discounted cash flow (DCF) model with a WACC of 6.2% and a perpetual growth rate of 3% [5][16].